Ishita Drugs & Industries Secures Rs 11.75 Crore Loan from HDFC Bank

Total credit facility sanctioned is Rs 11.75 crore including a Rs 9.75 crore term loan.
Funds are earmarked for upgrading the Sanand facility to meet Revised Schedule M compliance.

Reader Takeaway: The loan supports critical infrastructure compliance in Gujarat, though it increases the company's debt burden.

What just happened

Ishita Drugs & Industries Limited entered into a credit agreement with HDFC Bank Limited on September 22, 2026. The bank has sanctioned a total credit limit of Rs 11.75 crore. This includes Rs 9.75 crore as a term loan and Rs 2.00 crore designated for working capital requirements.

Why this matters

The capital infusion is specifically allocated for an upgradation project at the company's manufacturing site in Sanand, Ahmedabad. This investment is crucial for the company to achieve compliance with Revised Schedule M standards, which are mandatory requirements for pharmaceutical manufacturing operations in India.

Security and Terms

To secure the credit facility, Ishita Drugs has created a first charge on its movable and immovable assets located at Survey No. 179/1, Village Vasna Iyava, Sanand Viramgam Highway. The company clarified that the loan agreement contains no special rights for the lender, such as board representation or share subscription rights, and confirms the transaction does not involve any related parties.

What to track next

Investors should monitor the timeline for the completion of the Sanand facility upgrade and any subsequent impact on operational efficiency or production output once the new standards are implemented.